Ana Vega

Real-world, Multicenter Experience With Meropenem-Vaborbactam for Gram-Negative Bacterial Infections Including Carbapenem-Resistant <i>Enterobacterales</i> and <i>Pseudomonas aeruginosa</i>

Sara Alosaimy, Abdalhamid M Lagnf, Taylor Morrisette et al. · Open Forum Infectious Diseases · 2021 · 51 citations · Full text

Predictors of mortality and clinical characteristics among carbapenem-resistant or carbapenemase-producing Enterobacteriaceae bloodstream infections in Spanish children

María Fátima Ara Montojo, Luis Escosa‐García, Marina Alguacil-Guillén et al. · Journal of Antimicrobial Chemotherapy · 2020 · 50 citations

Effects of Tocilizumab in COVID-19 patients: a cohort study

Christine Vu, Kailynn DeRonde, Ana Vega et al. · BMC Infectious Diseases · 2020 · 38 citations · Full text

Effectiveness of ceftazidime–avibactam versus ceftolozane–tazobactam for multidrug-resistant Pseudomonas aeruginosa infections in the USA (CACTUS): a multicentre, retrospective, observational study

Ryan K. Shields, Lilian M. Abbo, Renee Ackley et al. · The Lancet Infectious Diseases · 2024 · 38 citations

Antimicrobial Susceptibility, Antibiotics, Medicine +11

Antimicrobial usage at a large teaching hospital in Lusaka, Zambia

Anne M. Masich, Ana Vega, Patricia Callahan et al. · PLoS ONE · 2020 · 37 citations · Full text

Hospital Medicine, Antibiotics, Antimicrobial Stewardship +13